Answers are grounded in this paper and cite their sources.
Background High energy meal plans (HEMP) are increasingly used in paediatric inpatient eating disorder care. This study aimed to determine the impact of HEMP on rate of weight gain, refeeding syndrome (RFS), nasogastric tube (NGT) use and length of stay (LOS), in paediatric eating disorder inpatients with Anorexia Nervosa (AN) or Atypical Anorexia Nervosa (AAN), compared with low energy meal plans (LEMP). Method A retrospective pre-post observational study was undertaken on a paediatric ward in Melbourne. Patients with AN or AAN requiring admission under the paediatric eating disorder protocol for nutritional rehabilitation from 15/03/2020–16/03/2023 were included. Patients admitted prior to September 16, 2022, were treated with LEMP (minimum of 1890 kcal/day). Following a change of practice, patients admitted after September 16, 2022, were treated with HEMP (minimum of 2512 kcal/day). Under hospital protocol, patients at significant risk received prophylactic phosphate. Results 237 patients commenced treatment on LEMP, and 165 patients on HEMP. Weight gain was faster with HEMP than LEMP (2.17 kg/week (SD 0.930) vs. 1.85 kg/week (SD 1.131); p = 0.002). HEMP patients were more often classified as being at significant risk of RFS at baseline (58.8% vs. 22.8%; p < 0.001). Phosphate supplementation was common in both groups and, consistent with baseline risk, more frequent with HEMP (84.2% vs. 63.3%; p < 0.001), with similar indications for supplementation and rates of hypophosphatemia between groups. No patients in either group developed RFS. Hypoglycaemia was less common with HEMP (32.1% vs. 47.3%; p = 0.002). There was no significant difference in NGT use (20.6% vs. 15.5%; p = 0.196) or median LOS (HEMP 13 days [IQR 10–16] vs. LEMP 12 days [IQR 8–16]; p = 0.104). Conclusions HEMP was associated with faster weight gain and less hypoglycaemia than LEMP, with no increase in RFS or hypophosphatemia. Prophylactic phosphate supplementation was common in both groups, and its greater use with HEMP likely reflects higher baseline RFS risk rather than energy prescription. LOS did not differ, possibly reflecting differences in illness severity and bed pressures between study periods. These findings support HEMP as a safe and effective approach to refeeding in medically unstable adolescents with AN/AAN when combined with phosphate monitoring.
No takes yet. Share an insight, caveat, or question.
Bissett et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: